AhmadTarhiniMDPhD

Hematologic Oncology, Melanoma

Director, Cutaneous Clinical and Translational Research

Overview of Dr. Tarhini

Dr. Ahmad Tarhini is an oncologist in Tampa, FL and is affiliated with multiple hospitals in the area, including H. Lee Moffitt Cancer Center and Research Institute, UPMC Presbyterian, UPMC Magee-Womens Hospital, and Shadyside Campus. Dr. Tarhini accepts several types of health insurance, listed below. He is one of 148 doctors at UPMC Presbyterian and one of 82 doctors at UPMC Magee-Womens Hospital who specialize in Oncology.

Office
Moffitt Cancer Center
12902 USF Magnolia Dr
Tampa, FL 33612
Book by Phone(813) 531-7912
Fax(404) 778-2177
Is this information wrong?

Education & Training

University of Pittsburgh Medical CenterFellowship, Hematology/Oncology, 2003 - 2006
University of Pittsburgh Medical CenterResidency, Internal Medicine, 2000 - 2003

Certifications & Licensure

FL State Medical License 2019 - 2021
GA State Medical License 2018 - 2020
OH State Medical License 2017 - 2019
PA State Medical License 2001 - 2018
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study Start of enrollment: 2016 Jun 01Ahmad Tarhini, MD
High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery Start of enrollment: 2015 Oct 01Averbook B.J.,Behrens R.J.,Grossmann K.,Grossmann K.F.,Kuebler J.P.,Patel S.P.,Puzanov I.,Schwartz M.A.,Steen P.D.,Tarhini A.A.,Vadakara J.J.,Wade J.L.
A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV Melanoma Start of enrollment: 2013 Dec 01Wong, S.,Hyzinski, M.,Wade, J.D.,McNamara, D.M.,Hodi, F.S.,Fagbemi, S.,Tarhini, A.,Zaren, H.A.,Merchant, J.J.,Ellerton, J.A.,Dakhil, S.R.,Albertini, M.R.,Movva, S.,Lawson, D.H.,Spector, D.M.,Butler, T.W.,...
A Phase III Randomized, 3-arm, Open Label, Multicenter Study of LGX818 Plus MEK162 and LGX818 Monotherapy Compared With Vemurafenib in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma Start of enrollment: 2013 Sep 01Feun, L.G.,Cosgriff, T.M.,Packer, S.H.,Panella, T.J.,Garrison, M.,O'Day, S.J.,Niederman, T.M.,Wender, D.B.,Pecora, A.L.,Mazurczak, M.A.,Spira, A.I.,Beck, J.M.,Slater, D.,Starodub, A.N.,Hauke, R.J.,Tarhini...
Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. Start of enrollment: 2013 Jul 01Schwarzberg, A.,Tarhini, A.,Salama, A.,Chmielowski, B.,Daniels, G.,Kluger, H.,Sosman, J.A.,Stephenson, J.J.,Kendra, K.,Margolin, K.,Spitler, L.,Ernstoff, M.S.,Taylor, M.,Postow, M.K.,Kittaneh, M.,Khushala...
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Start of enrollment: 2013 Jul 01Butler, T.,Beck, J.T.,O'Day, S.,Wong, M.K.,Minor, D.,Sikic, B.,Atkins, M.,Wright, D.D.,Reeves, J.,Hallmeyer, S.,Starodub, A.N.,Berg, S.E.,Kumar, P.P.,Flaherty, K.T.,Flaherty, L.,Gribbin, T.,Rudrapatna, V....
A Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10 mg/kg Alone or in Combination With High Dose Interferon-Alpha in Advanced Melanoma Start of enrollment: 2013 Jan 01Dakhil, S.R.,Wade, J.L.,Sturtz, K.B.,Einhorn, H.E.,Wender, D.B.,Zaren, H.A.,Wade, J.D.,Spector, D.M.,Kuebler, J.P.,Falkson, C.I.,Behrens, R.J.,Cohen, G.I.,Masters, G.A.,Leach, J.W.,Egner, J.R.,Payne, J.E....
A Phase I Study of ARQ 197 in Combination With IV Topotecan in Advanced Solid Tumors With an Expansion Cohort in Small Cell Lung Cancer Start of enrollment: 2012 Jul 01Tarhini, A.,Belani, C.P.,Gadgeel, S.M.,Koehler, S.,Gandara, D.R.,Hu, J.S.,Gitlitz, B.
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma Start of enrollment: 2012 Apr 01Tarhini, A.,Berg, A.,Liem, A.,Salama, A.,McClay, E.,, F.p.,Homsi, J.,Burke, J.,Hrom, J.,Lutzky, J.,Flaherty, L.,Rammage, M.,Kosty, M.,Shtivelband, M.,Gabrail, N.,Hamid, O.,Jiang, P.,Agarwala, S.,Jang, S.,...
A Phase I/II Trial of AMG 102 and Erlotinib in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2011 Aug 01Johnson, R.,Tarhini, A.
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Start of enrollment: 2011 May 01Riker, A.I.,Tarhini, A.A.,Tarhini, A.,Ikeguchi, A.P.,Bowers, C.E.,Wos, E.J.,Abesada-Terk, G.,Stoutenburg, J.P.,Treisman, J.S.,Clark, J.I.,Tirona, M.R.,Le-Lindqwister, N.A.,Veldhuizen, P.J.,Qamar, R.,Cesco...
Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery Start of enrollment: 2011 Jan 01Awasthi, S.,Lenz, H.,Koehler, S.C.,Christensen, S.D.,Lewis, K.D.,Lawson, D.H.,Kuzel, T.M.,Logan, T.F.,Flaherty, L.E.,Flynn, P.J.,Ernstoff, M.S.,Khushalani, N.I.,Koon, H.B.,Olencki, T.E.,Belani, C.P.,Tarhi...
A Phase II Randomized Trial of Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer Who Have Received First-line Platinum-based Chemotherapy With or Without Bevacizumab Start of enrollment: 2010 Sep 01Tarhini, A.
Neoadjuvant Anti-CTLA4 Blockade With Ipilimumab in Patients With AJCC Stage IIIB-C (Tx,1-4, N1b,2b, 2c, 3, M0) Melanoma: Immunogenicity And Biomarker Analysis Start of enrollment: 2009 Dec 01Tarhini, A.
Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer Start of enrollment: 2009 Sep 01Tarhini, A.A.
Pilot Analysis of the Effects of IFN Î±2b Upon the Molecular Profile of Regional Lymph Nodes in Melanoma Patients With and Without Tumor-Involved Sentinel Lymph Nodes Start of enrollment: 2009 Sep 01Connelly, K.L.,Tarhini, A.,Tarhini, A.A.
Pemetrexed and LBH589 in Previously-Treated Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2009 Jul 01Johnson, R.,Tarhini, A.
CTP (Computed Tomography Perfusion) Imaging of Lung Cancer Start of enrollment: 2009 Jun 01Gibson, M.K.,Socinski, M.A.,Tarhini, A.
Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2008 Oct 01Tarhini, A.A.
Phase I/II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy (UPCI 07-154) Start of enrollment: 2008 Sep 01Boyiadzis, M.
Sentinel Node and Non-Sentinel Lymph Nodes (SLN and Non-SLN) Procurement From Melanoma Subjects for Molecular Profiling Analysis Start of enrollment: 2008 May 01Tarhini, A.
VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2007 Jun 01Tarhini, A.
Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma Start of enrollment: 2006 Nov 01Tarhini, A.
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma Start of enrollment: 2006 Oct 01Tarhini, A.A.
Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors Ahmad Tarhini
http://clinicaltrials.gov/ct2/show/NCT02736123
Join now to see all

Publications & Presentations

PubMed

Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma
Lisa H. Butterfield, Lazar Vujanovic, Patricia M. Santos, Deena M. Maurer, Andrea Gambotto, Joel Lohr, Chunlei Li, Jacob K. Waldman, Uma R. Chandran, Yan Lin, Huang Li...> ;Journal for ImmunoTherapy of Cancer. 2019 Apr 24
Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison.
Michael B. Atkins, Ahmad Tarhini, Michael Rael, Komal Gupte-Singh, Elliott O'Brien, Corey Ritchings, Sumati Rao, David F. McDermott> ;Immunotherapy. 2019 Mar 11
Treatment patterns and outcomes for patients with unresectable stage III and metastatic melanoma in the USA.
Ahmad Tarhini, Christopher Atzinger, Komal Gupte-Singh, Courtney Johnson, Cynthia Macahilig, Sumati Rao> ;Journal of Comparative Effectiveness Research. 2019 Mar 5
Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma.
Ahmad Tarhini, David F. McDermott, Apoorva Ambavane, Komal Gupte-Singh, Valerie Aponte-Ribero, Corey Ritchings, Agnes Benedict, Sumati Rao, Meredith M. Regan, Michael ...> ;Immunotherapy. 2019 Mar 1
Stage III melanoma incidence and impact of transitioning to the 8th AJCC staging system: a US population-based study.
Ahmad Tarhini, Sameer R. Ghate, Raluca Ionescu-Ittu, Sherry Shi, Antonio Nakasato, Briana Ndife, François Laliberté, Rebecca Burne, Mei Sheng Duh> ;Future Oncology. 2019 Feb 1
An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles.
Angelica Ortiz, Jun Gui, Farima Zahedi, Pengfei Yu, Christina Cho, Sabyasachi Bhattacharya, Christopher J. Carbone, Qiujing Yu, Kanstantsin V. Katlinski, Yuliya V. Kat...> ;Cancer Cell. 2019 Jan 14
Cases from the irAE Tumor Board: A Multidisciplinary Approach to a Patient Treated with Immune Checkpoint Blockade Who Presented with a New Rash.
Pradnya D. Patil, Anthony P. Fernandez, Vamsidhar Velcheti, Ahmad Tarhini, Pauline Funchain, Brian I. Rini, Mohamad Khasawneh, Nathan A. Pennell> ;Oncologist. 2019 Jan 1
Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine.
Ahmad Tarhini, Ragini R. Kudchadkar> ;Cancer Treatment Reviews. 2018 Dec 1
Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma.
Ahmad Tarhini, Sameer R. Ghate, Raluca Ionescu-Ittu, Ameur M. Manceur, Briana Ndife, Philippe Jacques, François Laliberté, Antonio Nakasato, Rebecca Burne, Mei Sheng Duh> ;Melanoma Research. 2018 Dec 1
NCI 8628: A randomized phase 2 study of ziv‐aflibercept and high‐dose interleukin 2 or high‐dose interleukin 2 alone for inoperable stage III or IV melanoma
Ahmad A. Tarhini, Paul Frankel, Christopher Ruel, Marc S. Ernstoff, Timothy M. Kuzel, Theodore F. Logan, Nikhil I. Khushalani, Hussein Abdul-Hassan Tawbi, Kim Margolin...> ;Cancer. 2018 Nov 15
Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis.
Ahmad Tarhini, Agnes Benedict, David F. McDermott, Sumati Rao, Apoorva Ambavane, Komal Gupte-Singh, J Sabater, Corey Ritchings, Valerie Aponte-Ribero, Meredith M. Rega...> ;Immunotherapy. 2018 Sep 3
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.
Hussein Abdul-Hassan Tawbi, Peter A. Forsyth, Alain Patrick Algazi, Omid Hamid, F. Stephen Hodi, Stergios J. Moschos, Nikhil I. Khushalani, Karl D. Lewis, Christopher ...> ;The New England Journal of Medicine. 2018 Aug 22
Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non–small cell lung cancer
Ahmad A. Tarhini, Imran Rafique, Theofanis Floros, Phu Tran, William E. Gooding, Liza C. Villaruz, Timothy F. Burns, David M. Friedland, Daniel P. Petro, Mariya Farooq...> ;Cancer. 2017 Aug 1
A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG‐ACRIN Cancer Research Group (E...
Kevin Kalinsky, Sandra J. Lee, Krista M. Rubin, Donald P. Lawrence, Anthony J. Iafrarte, Darell R. Borger, Kim Margolin, Mario M. Leitao, Ahmad A. Tarhini, Henry B. Ko...> ;Cancer. 2017 Jul 15
Operable Melanoma: Screening, Prognostication, and Adjuvant and Neoadjuvant Therapy.
Tarhini, A. A.,Lorigan, P.,Leachman, S.> ;Am Soc Clin Oncol Educ Book. 2017 May 01
Vaccine therapy + dasatinib for the treatment of patients with stage IIIB-IV melanoma.
Ahmad A. Tarhini, Hussein Abdul-Hassan Tawbi, Walter J. Storkus> ;Melanoma management. 2016 Nov 29
Future perspectives in melanoma research
Paolo A. Ascierto, Sanjiv S. Agarwala, Gerardo Botti, Alessandra Cesano, Gennaro Ciliberto, Michael A. Davies, Sandra Demaria, Reinhard Dummer, Alexander M.M. Eggermon...> ;Journal of Translational Medicine. 2016 Nov 15
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
C. Boutros, Ahmad A. Tarhini, Emilie Routier, Olivier Lambotte, Francois Leroy Ladurie, Franck Carbonnel, Hassane Izzeddine, Aurélien Marabelle, Stéphane Champiat, Arm...> ;Nature Reviews Clinical Oncology. 2016 Aug 1
Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG).
Christopher J. Anker, Kenneth F. Grossmann, Michael B. Atkins, Gita Suneja, Ahmad A. Tarhini, John M. Kirkwood> ;International Journal of Radiation Oncology Biology Physics. 2016 Jun 1
Annual Hospital Volume of High Dose Interleukin-2 and Inpatient Mortality in Melanoma and Renal Cell Carcinoma Patients.
Kathan Mehta, Leonard Joseph Appleman, Hong Wang, Ahmad A. Tarhini, Rahul A. Parikh> ;PLOS ONE. 2016 Jan 22
Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
Ahmad A. Tarhini, Haris Zahoor, Yan Lin, Usha Malhotra, Cindy Sander, Lisa H. Butterfield, John M. Kirkwood> ;Journal for ImmunoTherapy of Cancer. 2015 Sep 15
Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plu...
David H. Lawson, Sandra J. Lee, Fengmin Zhao, Ahmad A. Tarhini, Kim Margolin, Marc S. Ernstoff, Michael B. Atkins, Gary Cohen, Theresa L. Whiteside, Lisa H. Butterfiel...> ;Journal of Clinical Oncology. 2015 Sep 8
Intermediate-grade meningeal melanocytoma associated with nevus of Ota: a case report and review of the literature.
Donghoon Shin, Milind Sinha, Douglas Kondziolka, John M. Kirkwood, Uma N. M. Rao, Ahmad A. Tarhini> ;Melanoma Research. 2015 Aug 1
Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients
Ahmad A. Tarhini, Yan Lin, Haris Zahoor, Yongli Shuai, Lisa H. Butterfield, Steven Ringquist, Helen Gogas, Cindy Sander, Sandra J. Lee, Sanjiv S. Agarwala, John M. Kir...> ;PLOS ONE. 2015 Jul 20
Immunotherapy of Melanoma.
Tarhini, A. A., Tarhini, A. A.> ;Current molecular pharmacology. 2015 Jul 17
Join now to see all

Lectures

United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-Î±2b for resected high-risk melanoma.
2019 ASCO Annual Meeting - 6/1/2019
Clinical and economic outcomes associated with sequential treatment in BRAF mutant advanced melanoma patients.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Association of Community Cancer Centers(ACCC) 30th National Conference
Association of Community Cancer Centers (ACCC), Boston, Massachusetts - 10/2/2013
Association of Community Cancer Centers(ACCC) 30th National Conference
Association of Community Cancer Centers (ACCC), Boston, Massachusetts - 10/2/2013
Join now to see all

Authored Content

Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition with Pembrolizumab Outcomes in Advanced MelanomaJuly 2020
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition with Pembrolizumab Outcomes in Advanced MelanomaJuly 2020

Press Mentions

Should Nicotinamide Be Used for Melanoma Prevention?October 24, 2020 18:59
CURE’s Clinical Trial Corner: September 2020October 11, 2020 20:52
A One-Day Melanoma Refresh with Cleveland Clinic ExpertsJuly 27, 2018 18:02
Join now to see all

Hospital Affiliations

H. Lee Moffitt Cancer Center and Research InstituteTampa, Florida
UPMC PresbyterianPittsburgh, Pennsylvania
UPMC Magee-Womens HospitalPittsburgh, Pennsylvania
Shadyside CampusPittsburgh, Pennsylvania

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Texas BlueChoice
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Coventry Oklahoma
First Choice
First Health PPO
Great West PPO
Health Net Oregon PPO
HealthAmerica HealthAssurance PPO
Highmark BCBS ClassicBlue
Highmark BCBS PPOBlue
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
ODS Network
Providence Health System Personal Option
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment